Analysis of incomplete durations with application to contraceptive useALI, Mohamed M; MARSHALL, Tom; BABIKER, Abdel G et al.Journal of the Royal Statistical Society. Series A. Statistics in society (Print). 2001, Vol 164, Num 3, pp 549-563, issn 0964-1998Article

Impact of missing data due to selective dropouts in cohort studies and clinical trialsTOULOUMI, Giota; POCOCK, Stuart J; BABIKER, Abdel G et al.Epidemiology (Cambridge, Mass.). 2002, Vol 13, Num 3, pp 347-355, issn 1044-3983Article

Mother-to-child transmission of HIV-1 and infant feeding practiceWALKER, A. Sarah; BABIKER, Abdel G; GIBB, Diana M et al.AIDS (London). 2001, Vol 15, Num 10, pp 1327-1328, issn 0269-9370Article

HIV drug resistance testing: is the evidence really there?DUNN, David T; GIBB, Diana M; BABIKER, Abdel G et al.Antiviral therapy (London). 2004, Vol 9, Num 5, pp 641-648, issn 1359-6535, 8 p.Article

A randomized controlled trial of genotypic HIV drug resistance testing in HIV-1-infected children : the PERA (PENTA 8) TrialGREEN, Hannah; GIBB, Diana M; ABOULKER, Jean-Pierre et al.Antiviral therapy (London). 2006, Vol 11, Num 7, pp 857-867, issn 1359-6535, 11 p.Article

Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1:96 week results from the NEAT001/ANRS143 randomised non-inferiority trialRAFFI, François; BABIKER, Abdel G; SAILLARD, Juliette et al.Lancet (British edition). 2014, Vol 384, Num 9958, pp 1942-1951, issn 0140-6736, 10 p.Article

A virological benefit from an induction/maintenance strategy: the forte trialASBOE, David; WILLIAMS, Ian G; GOODALL, Ruth L et al.Antiviral therapy (London). 2007, Vol 12, Num 1, pp 47-54, issn 1359-6535, 8 p.Article

Analysis of failure time hierarchical data in the presence of competing risks with application to oral contraceptive pill use in EgyptALI, Mohamed M; BABIKER, Abdel G; CLELAND, John G et al.Statistics in medicine. 2001, Vol 20, Num 23, pp 3611-3624, issn 0277-6715Article

Early antiretroviral therapy improves neurodevelopmental outcomes in infantsLAUGHTON, Barbara; CORNELL, Morna; JEAN-PHILIPPE, Patrick et al.AIDS (London). 2012, Vol 26, Num 13, pp 1685-1690, issn 0269-9370, 6 p.Article

Mortality after Fluid Bolus in African Children with Severe InfectionMAITLAND, Kathryn; KIGULI, Sarah; BRENT, Bernadette et al.The New England journal of medicine. 2011, Vol 364, Num 26, pp 2483-2495, issn 0028-4793, 13 p.Article

Early Antiretroviral Therapy and Mortality among HIV-Infected InfantsVIOLARI, Avy; COTTON, Mark F; GIBB, Diana M et al.The New England journal of medicine. 2008, Vol 359, Num 21, pp 2233-2244, issn 0028-4793, 12 p.Article

Differences in HIV RNA levels before the initiation of antiretroviral therapy among 1864 individuals with known HIV-1 seroconversion datesTOULOUMI, Giota; PANTAZIS, Nikos; BABIKER, Abdel G et al.AIDS (London). 2004, Vol 18, Num 12, pp 1697-1705, issn 0269-9370, 9 p.Article

Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial)GIBB, Diana M; WALKER, A. Sarah; BABIKER, Abdel G et al.Antiviral therapy (London). 2002, Vol 7, Num 4, pp 293-303, issn 1359-6535, 11 p.Article